News: Baxter International Inc (BAX)

BAX on New York Consolidated

73.49USD
17 Sep 2014
Price Change (% chg)

$-1.50 (-2.01%)
Prev Close
$74.99
Open
$74.50
Day's High
$74.50
Day's Low
$73.31
Volume
1,474,741
Avg. Vol
2,106,307
52-wk High
$77.31
52-wk Low
$62.80

Search Stocks
Select another date:

Thu, Aug 21 2014

Long-acting version of Baxter's hemophilia drug succeeds in study

- Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

Long-acting version of Baxter's hemophilia drug succeeds in study

Aug 21 - Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

UPDATE 2-FDA panel: Benefit of Baxter's immune therapy outweighs risk

WASHINGTON, July 31 - The benefit of Baxter International Inc's experimental immune deficiency therapy, HyQvia, outweighs the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday.

FDA panel: Benefit of Baxter's immune therapy outweighs risk

- The benefits associated with Baxter International Inc's experimental treatment for certain diseases of the immune system outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday, paving the way for approval of the therapy.

FDA panel: Benefit of Baxter's immune therapy outweighs risk

July 31 - The benefits associated with Baxter International Inc's experimental treatment for certain diseases of the immune system outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday, paving the way for approval of the therapy.

U.S. FDA panel reviews Baxter immune therapy's long-term safety

Washington - Advisors to the U.S. Food and Drug Administration will meet on Thursday to discuss the relative risks and benefits of Baxter International Inc's experimental treatment for certain hereditary disorders of the immune system.

U.S. FDA panel reviews Baxter immune therapy's long-term safety

Washington, July 30 - Advisors to the U.S. Food and Drug Administration will meet on Thursday to discuss the relative risks and benefits of Baxter International Inc's experimental treatment for certain hereditary disorders of the immune system.

Pfizer to buy Baxter's vaccines unit for $635 million

- Pfizer Inc agreed on Wednesday to buy Baxter International Inc's vaccines unit and a part of a production facility for $635 million.

UPDATE 1-Pfizer to buy Baxter's vaccines unit for $635 mln

July 30 - Pfizer Inc agreed on Wednesday to buy Baxter International Inc's vaccines unit and a part of a production facility for $635 million.

CORRECTED-Pfizer to buy two Baxter vaccines for $635 mln

(Corrects third paragraph to " ... outside the United States" from " ... in the United States")

Select another date:
Search Stocks